RUA — Rua Life Sciences Share Price
Last trade - 00:00- £7.06m
- £7.01m
- £2.18m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.89 | ||
| Price to Tang. Book | 2.36 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.78 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -59.75% | ||
| Return on Equity | -40.56% | ||
| Operating Margin | -135.37% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.46 | 0.49 | 1.53 | 1.63 | 2.18 | 2.23 | 3.3 | 40.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RUA Life Sciences plc is a United Kingdom-based holding company of a group of medical device businesses focused on the exploitation of long-term implantable biostable polymer (Elast-Eon). Elast-Eon's biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. The Company has four business units: RUA Contract Manufacture, RUA Biomaterials, RUA Vascular and RUA Structural Heart. RUA Contract Manufacture is an end-to-end contract developer and manufacturer of medical devices and implantable fabric specialist. It provides sub-contract manufacturing, assembly, packing and services to the medical device sector from its Class 7 and 8 cleanroom suites. RUA Biomaterials is a licensor of Elast-Eon polymers to the medical device industry. RUA Vascular is engaged in the commercialization of open surgical vascular grafts and patches. RUA Structural Heart is engaged in the development of polymeric leaflet systems for heart valves.
Directors
- William Brown CHM (57)
- Caroline Stretton COO
- John Mckenna EDR (67)
- Ian Ardill NED
- Geoffrey Berg NID
- John Ely NID
- Last Annual
- March 31st, 2023
- Last Interim
- September 30th, 2023
- Incorporated
- November 21st, 1996
- Public Since
- February 12th, 1997
- No. of Employees
- 40
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 62,060,272
- Address
- 2 Drummond Crescent, Irvine, AYRSHIRE, KA11 5AN
- Web
- https://rualifesciences.com/
- Phone
- +44 1294317073
- Auditors
- Grant Thornton UK LLP
Latest News for RUA
Upcoming Events for RUA
Full Year 2024 Rua Life Sciences PLC Earnings Release
Similar to RUA
Abingdon Health
London Stock Exchange
Advanced Medical Solutions
London Stock Exchange
Advanced Oncotherapy
London Stock Exchange
Angle
London Stock Exchange
Aptamer
London Stock Exchange
FAQ
As of Today at 07:19 UTC, shares in Rua Life Sciences are trading at 11.38p. This share price information is delayed by 15 minutes.
Shares in Rua Life Sciences last closed at 11.38p and the price had moved by -73.85% over the past 365 days. In terms of relative price strength the Rua Life Sciences share price has underperformed the FTSE All Share Index by -75.18% over the past year.
The overall consensus recommendation for Rua Life Sciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Rua Life Sciences does not currently pay a dividend.
Rua Life Sciences does not currently pay a dividend.
Rua Life Sciences does not currently pay a dividend.
To buy shares in Rua Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 11.38p, shares in Rua Life Sciences had a market capitalisation of £7.06m.
Here are the trading details for Rua Life Sciences:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: RUA
Based on an overall assessment of its quality, value and momentum Rua Life Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Rua Life Sciences is 25.00p. That is 119.78% above the last closing price of 11.38p.
Analysts covering Rua Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of -£0.04 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rua Life Sciences. Over the past six months, its share price has underperformed the FTSE All Share Index by -16.46%.
As of the last closing price of 11.38p, shares in Rua Life Sciences were trading -21.41% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rua Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 11.38p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Rua Life Sciences' management team is headed by:
- William Brown - CHM
- Caroline Stretton - COO
- John Mckenna - EDR
- Ian Ardill - NED
- Geoffrey Berg - NID
- John Ely - NID